Clinical studies with curcumin
Journal
Advances in Experimental Medicine and Biology
Journal Volume
595
Pages
471-480
Date Issued
2007
Author(s)
Abstract
Curcumin has long been expected to be a therapeutic or preventive agent for several major human diseases because of its antioxidative, anti-inflammatory, and anticancerous effects. In phase I clinical studies, curcumin with doses up to 3600-8000 mg daily for 4 months did not result in discernible toxicities except mild nausea and diarrhea. The pharmacokinetic studies of curcumin indicated in general a low bioavailability of curcumin following oral application. Nevertheless, the pharmacologically active concentration of curcumin could be achieved in colorectal tissue in patients taking curcumin orally and might also be achievable in tissues such as skin and oral mucosa, which are directly exposed to the drugs applied locally or topically. ? 2007 Springer.
SDGs
Other Subjects
curcumin; demethoxycurcumin; didemethoxycurcumin; gemcitabine; Ginkgo biloba extract; phenylbutazone; piperine; placebo; sulindac; unclassified drug; alkaline phosphatase blood level; antiinflammatory activity; antineoplastic activity; cancer chemotherapy; chronic pancreatitis; clinical trial; colorectal cancer; diarrhea; drug bioavailability; drug blood level; drug dose escalation; drug effect; drug efficacy; drug formulation; drug safety; enteritis; feces color; gastrointestinal disease; headache; human; hyperlipidemia; iridocyclitis; lactate dehydrogenase blood level; nausea; precancer; priority journal; psoriasis; rash; review; rheumatoid arthritis; side effect; unspecified side effect
Publisher
Springer New York
Type
review